BRD4 and ovarian cancer: Accordingly, to evaluate the global effect of AZD5153, a novel, potent, and specific BRD4 inhibitor (18) in the TME of ovarian cancer, we profiled BET inhibitory effects on TAMs in vitro and in vivo.